Clinical Trials Logo

Ewing Sarcoma clinical trials

View clinical trials related to Ewing Sarcoma.

Filter by:
  • Recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06340204 Recruiting - Ewing Sarcoma Clinical Trials

Weekly Irinotecan Liposomes in Recurrent or Refractory Ewing Sarcoma

Start date: March 25, 2024
Phase: Phase 1
Study type: Interventional

The investigators explored the safety and activity of weekly irinotecan liposomes in patients with relapsed and metastatic Ewing Sarcoma.

NCT ID: NCT06243588 Recruiting - Ewing Sarcoma Clinical Trials

Identification of Prognostic Factors and Role of Radiotherapy in Patients With Ewing Sarcoma

Start date: January 25, 2024
Phase:
Study type: Observational

assess whether there is a correlation between some factors (age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation and biomarkers) and overall survival (OS) and relapse-free survival (RFS) in patients with Ewing sarcoma. Identification of reliable prognostic factors could help to identify high-risk patients, which may require a different treatment and follow up.

NCT ID: NCT06156410 Recruiting - Osteosarcoma Clinical Trials

Cabozantinib With Ifosfamide in Ewing's Sarcoma and Osteosarcoma

Start date: October 24, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.

NCT ID: NCT06094101 Recruiting - Rhabdomyosarcoma Clinical Trials

Personalized Vaccination in Fusion+ Sarcoma Patients (PerVision)

PerVision
Start date: September 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The PerVision trial utilizes an approach of a patient-individual cancer vaccine with sarcoma-specific peptides in metastasized fusion-driven sarcoma patients determined by next generation whole exome sequencing of tumor and normal tissue as well as RNA sequencing of the tumor. This approach is applicable to all patients independent of the expression of distinct tumor associated antigens, and independent of their human leukocyte antigen-typing (HLA-typing). The results of this study can directly be translated to other tumor entities. It is an interventional, multicenter, open-label, phase I/II feasibility and early proof of concept study evaluating a personalized peptide vaccine. Primary objective is to evaluate safety and success of treatment, the latter be defined as vaccination-induced T-cell response without unacceptable toxicity.

NCT ID: NCT06068075 Recruiting - Ewing Sarcoma Clinical Trials

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Start date: May 8, 2018
Phase: N/A
Study type: Interventional

This is a prospective multicenter biomarker study evaluating the prognostic impact of ctDNA detection at diagnosis in patients with Ewing sarcoma or osteosarcoma.

NCT ID: NCT06029218 Recruiting - Osteosarcoma Clinical Trials

Analysis of the Toxicity and Efficacy of Daily 1 vs 2 Beam Proton Therapy

P1V2
Start date: September 13, 2023
Phase: N/A
Study type: Interventional

Thanks to the intrinsic qualities of the proton beam, proton therapy will reduce adverse effects of irradiation. The Proteus®One is the latest generation of proton therapy equipment, enabling the Centre Antoine Lacassagne to expand its range of treatments by carrying out new proton therapy treatments. It has an innovative compact isocentric rotating head (Gantry) that allows the radiation beam to be directed at different angles around the patient. In some cases, two beams are used to treat tumours, and by convention, both beams are delivered during the same session. However, it is necessary to position the patient before each beam, which is time-consuming because 2 beams have to be positioned very precisely each day. The aim of this study is therefore to assess the toxicity of proton therapy delivered by a single daily beam compared with proton therapy delivered by two daily beams, which is the conventional technique.

NCT ID: NCT05968768 Recruiting - Ewing Sarcoma Clinical Trials

To Evaluate the Efficacy and Safety of Naxitamab in Patients With Refractory Ewing's Sarcoma (Butterfly)

Start date: October 24, 2023
Phase: Phase 2
Study type: Interventional

Prospective, interventional, open, randomized, national, multicenter, non-commercial trial

NCT ID: NCT05918640 Recruiting - Pediatric Cancer Clinical Trials

Lurbinectedin in FET-Fused Tumors

LiFFT
Start date: July 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

NCT ID: NCT05779670 Recruiting - Osteosarcoma Clinical Trials

Adherence to a Personalized Home Exercise Program in Patients With Bone Tumor Undergoing Lower Extremity Salvage Surgery

ADER
Start date: January 1, 2023
Phase:
Study type: Observational

The objective of this study is to describe adherence to a personalised home exercise program in patients undergoing resection and reconstruction of lower limb for bone tumor and neoadjuvant chemotherapy treatment in the first six months after surgery intervention and investigate possible prognostic factors.

NCT ID: NCT05734066 Recruiting - Ewing Sarcoma Clinical Trials

Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

EMERGE 101
Start date: May 23, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is conducted in two phases. The phase 1 portion of the study evaluates the safety, tolerability, pharmacokinetics (PK), recommended phase 2 dose (RP2D), and effectiveness of lurbinectedin monotherapy in pediatric participants with previously treated solid tumors. This is followed by the phase 2 portion, to further assess the effectiveness and safety in pediatric and young adult participants with recurrent/refractory Ewing sarcoma.